{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:31:46Z","timestamp":1794486706001,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.vaccine.2023.12.047","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T13:59:39Z","timestamp":1707227979000},"page":"1230-1246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches"],"prefix":"10.1016","volume":"42","author":[{"given":"Adam","family":"Soble","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2695-1547","authenticated-orcid":false,"given":"Melissa","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-1127","authenticated-orcid":false,"given":"Stefano","family":"Malvolti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-4685","authenticated-orcid":false,"given":"Mateusz","family":"Hasso-Agopsowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2555-7756","authenticated-orcid":false,"given":"Birgitte","family":"Giersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Amorij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3046-6891","authenticated-orcid":false,"given":"Courtney","family":"Jarrahian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayad","family":"El Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7878-5598","authenticated-orcid":false,"given":"Marion","family":"Menozzi-Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4410-1060","authenticated-orcid":false,"given":"Tiziana","family":"Scarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2023.12.047_b0005","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1186\/s13063-022-06493-5","volume":"23","author":"Adigweme","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.vaccine.2023.12.047_b0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2015.11.019","article-title":"Microneedle patches for vaccination in developing countries","volume":"240","author":"Arya","year":"2016","journal-title":"J Controlled Release"},{"issue":"10","key":"10.1016\/j.vaccine.2023.12.047_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105045","article-title":"A microarray patch SARS-CoV-2 vaccine induces sustained antibody responses and polyfunctional cellular immunity","volume":"25","author":"Balmert","year":"2022","journal-title":"iScience"},{"issue":"10299","key":"10.1016\/j.vaccine.2023.12.047_b0020","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0140-6736(21)01337-4","article-title":"Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study","volume":"398","author":"Causey","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.047_b0025","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/21645515.2020.1804776","article-title":"Vaccines and routine immunization strategies during the COVID-19 pandemic","volume":"17","author":"Dinleyici","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"45","key":"10.1016\/j.vaccine.2023.12.047_b9005","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.15585\/mmwr.mm7045a1","article-title":"Progress Toward Regional Measles Elimination - Worldwide, 2000\u20132020","volume":"70","author":"Dixon","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"4","key":"10.1016\/j.vaccine.2023.12.047_b9000","doi-asserted-by":"crossref","first-page":"2050123","DOI":"10.1080\/21645515.2022.2050123","article-title":"Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer's perspective","volume":"18","author":"Forster","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.12.047_b0030","unstructured":"Gavi. Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan; 2022. https:\/\/www.gavi.org\/sites\/default\/files\/about\/market-shaping\/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf."},{"key":"10.1016\/j.vaccine.2023.12.047_b0035","unstructured":"Gavi, The Vaccine Innovation Prioritisation Strategy [Internet]; 2022 [accessed 2023]. https:\/\/www.gavi.org\/our-alliance\/market-shaping\/vaccine-innovation-prioritisation-strategy."},{"issue":"49","key":"10.1016\/j.vaccine.2023.12.047_b0040","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1016\/j.vaccine.2021.07.091","article-title":"Strategies for vaccine-product innovation: creating an enabling environment for product development to uptake in low- and middle-income countries","volume":"39","author":"Giersing","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.047_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.809675","article-title":"Accelerating the development of measles and rubella microarray patches to eliminate measles and rubella: recent progress, remaining challenges","volume":"10","author":"Hasso-Agopsowicz","year":"2022","journal-title":"Front Public Health"},{"issue":"8","key":"10.1016\/j.vaccine.2023.12.047_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004060","article-title":"Universal healthcare coverage and health service delivery before and during the COVID-19 pandemic: a difference-in-difference study of childhood immunization coverage from 195 countries","volume":"19","author":"Kim","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.12.047_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1037157","article-title":"Estimating the future global dose demand for measles\u2013rubella microarray patches","volume":"10","author":"Ko","year":"2023","journal-title":"Front Public Health"},{"issue":"49","key":"10.1016\/j.vaccine.2023.12.047_b0060","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.1016\/j.vaccine.2021.05.102","article-title":"A global collaboration to advance vaccine product innovations \u2013 The Vaccine Innovation Prioritisation Strategy","volume":"39","author":"Kristensen","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.047_b0065","doi-asserted-by":"crossref","first-page":"1165110","DOI":"10.3389\/fpubh.2023.1165110","article-title":"Exploring potential applications of measles and rubella microarray patches (MR-MAPs): use case identification","volume":"11","author":"Malvolti","year":"2023","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.047_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9020084","article-title":"The impact of rubella vaccine introduction on rubella infection and congenital rubella syndrome: a systematic review of mathematical modelling studies","volume":"9","author":"Motaze","year":"2021","journal-title":"Vaccines"},{"issue":"49","key":"10.1016\/j.vaccine.2023.12.047_b0075","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1016\/j.vaccine.2021.08.024","article-title":"Vaccine innovation prioritisation strategy: findings from three country-stakeholder consultations on vaccine product innovations","volume":"39","author":"Mvundura","year":"2021","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2023.12.047_b0080","doi-asserted-by":"crossref","first-page":"833","DOI":"10.15585\/mmwr.mm7023a1","article-title":"Progress toward rubella elimination - World Health Organization European Region, 2005\u20132019","volume":"70","author":"O'Connor","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"32","key":"10.1016\/j.vaccine.2023.12.047_b0090","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1016\/j.vaccine.2019.03.035","article-title":"Potential use of microarray patches for vaccine delivery in low- and middle- income countries","volume":"37","author":"Peyraud","year":"2019","journal-title":"Vaccine"},{"issue":"10095","key":"10.1016\/j.vaccine.2023.12.047_b0095","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","article-title":"The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial","volume":"390","author":"Rouphael","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.047_b0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/17425247.2023.2168641","article-title":"Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities","volume":"20","author":"Scarn\u00e0","year":"2023","journal-title":"Expert Opin Drug Deliv"},{"issue":"52","key":"10.1016\/j.vaccine.2023.12.047_b0105","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1016\/j.vaccine.2022.10.026","article-title":"Prevalence of pain and fear as barriers to vaccination in children \u2013 systematic review and meta-analysis","volume":"40","author":"Taddio","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.047_b0110","unstructured":"UNICEF and World Health Organization. Immunization coverage: are we losing ground?; 2020. https:\/\/data.unicef.org\/wp-content\/uploads\/2020\/07\/WUENIC-Immunization-coverage-are-we-losing-ground-brochure-2020.pdf."},{"key":"10.1016\/j.vaccine.2023.12.047_b0115","unstructured":"World Health Organization. Typhoid vaccines: WHO position paper - March 2018 Weekly Epidemiological Record, 30 March 2018, Vol. 93, 13; 2018. https:\/\/www.who.int\/publications\/i\/item\/whio-wer9313."},{"key":"10.1016\/j.vaccine.2023.12.047_b0120","unstructured":"World Health Organization. Pulse survey on continuity of essential health services during the COVID-19 pandemic: interim report, 27 August 2020; 2020. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-EHS_continuity-survey-2020.1."},{"key":"10.1016\/j.vaccine.2023.12.047_b0125","unstructured":"World Health Organization. Immunization and vaccine- related implementation research advisory committee (IVIR-AC), summary and recommendations, September 2020. Weekly Epidemiol Rec 2020;49:609\u201328. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/337339\/WER9549-eng-fre.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2023.12.047_b0130","unstructured":"World Health Organization, Global Report. Immunization agenda 2030 - a global strategy to leave no one behind; 2021. https:\/\/www.immunizationagenda2030.org\/."},{"key":"10.1016\/j.vaccine.2023.12.047_b0135","unstructured":"WUENIC: WHO\/UNICEF estimates of national immunization coverage. Progress and challenges with achieving universal immunization coverage; 2022. https:\/\/www.who.int\/publications\/m\/item\/progress-and-challenges."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:33:04Z","timestamp":1759404784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23014937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0264410X23014937"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}